Loading
AI
Athenex, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 30 Aug 2022.
Athenex, Inc.: what insiders have been doing
This page follows insider dealings at Athenex, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. The past year has been quiet: not a single insider filing for Athenex, Inc. The previous disclosure was published on 8 May 2023.
Looking back to 2021, when coverage begins, insiders filed 15 purchases and no sales.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
152
Thresholds
n/a
Buy Volume
€272,800
15 ops. · all time
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
RevenueUS$88.5M
Gross profitUS$23M26% margin
Net income-US$89.1M-100.6% margin
Last declaration on 8 May 2023
Declarations152 total
3,603 shares@ US$1.361.9% of flowCommon StockSEC:0001209191-23-027948:0
8,382 shares@ US$1.362.2% of flowCommon StockSEC:0001209191-23-027951:0
368 shares@ US$1.363.2% of flowCommon StockSEC:0001209191-23-027942:0
383 shares@ US$1.3053.2% of flowCommon StockSEC:0001209191-23-025394:0
6,513 shares@ US$1.30518.7% of flowCommon StockSEC:0001209191-23-025413:0
5,747 shares@ US$1.30519.2% of flowCommon StockSEC:0001209191-23-025401:0
3,642 shares@ US$1.30519.2% of flowCommon StockSEC:0001209191-23-025397:0
8,813 shares@ US$1.30519.2% of flowCommon StockSEC:0001209191-23-025410:0
2,300 shares@ US$1.30519.2% of flowCommon StockSEC:0001209191-23-025408:0
8,736 shares@ US$1.3052.2% of flowCommon StockSEC:0001209191-23-025405:0
3,755 shares@ US$1.3051.9% of flowCommon StockSEC:0001209191-23-025403:0
4,017 shares@ US$1.221.9% of flowCommon StockSEC:0001209191-23-024010:0
410 shares@ US$1.223.2% of flowCommon StockSEC:0001209191-23-024016:0
9,344 shares@ US$1.222.2% of flowCommon StockSEC:0001209191-23-024005:0
360 shares@ US$1.393.2% of flowCommon StockSEC:0001209191-23-021233:0
3,525 shares@ US$1.391.9% of flowCommon StockSEC:0001209191-23-021230:0
8,201 shares@ US$1.392.2% of flowCommon StockSEC:0001209191-23-021224:0
2,526 shares@ US$1.941.9% of flowCommon StockSEC:0001209191-23-018198:0
258 shares@ US$1.943.3% of flowCommon StockSEC:0001209191-23-018206:0
5,519 shares@ US$1.942.1% of flowCommon StockSEC:0001209191-23-018191:0
182 shares@ US$2.743.3% of flowCommon StockSEC:0001209191-23-013246:0
1,788 shares@ US$2.741.9% of flowCommon StockSEC:0001209191-23-013263:0
1,591 shares@ US$2.740.9% of flowCommon StockSEC:0001209191-23-013259:0
625 sharesCommon StockSEC:0001209191-23-013223:0
25 of 152 declarations
About Athenex, Inc.
Athenex, Inc. (ticker: ATNX) was a U.S.-listed biopharmaceutical company whose common stock traded on the Nasdaq Global Select Market, making it a NYSE/NASDAQ-style U.S. public-market name for investors following SEC disclosures and insider activity. The company was historically headquartered in Buffalo, New York, United States. It was formed in November 2003 as Kinex Pharmaceuticals LLC, began operations in February 2004, and later converted into a Delaware corporation in December 2012 before taking the Athenex name. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1300699/000095017023008734/atnx-20221231.htm?utm_source=openai))
From a business-model standpoint, Athenex was built as an oncology-focused biotech with a mix of research, development, manufacturing, and specialty commercialization. Its core scientific narrative centered on oral taxane delivery through the Orascovery platform, including oral paclitaxel and encequidar, alongside other technology platforms such as Src kinase inhibition, TCR-T cell therapy, and arginine deprivation approaches. The company’s historical pipeline also included candidates such as KX-01 and KX-02. In addition to clinical-stage development, Athenex operated commercial channels through Athenex Pharmaceutical Division (APD) and 503B compounding-related activities through Athenex Pharma Solutions (APS). ([sec.gov](https://www.sec.gov/Archives/edgar/data/1300699/000119312519313488/d838422dex991.htm?utm_source=openai))
Read moreShow less
Geographically, Athenex had a comparatively broad footprint for a mid-cap biotech, with U.S. offices and facilities in Buffalo, Clarence, Cranford, Houston, and Chicago, plus operations or offices in Hong Kong, Taipei, multiple locations in Chongqing, Manchester, Guatemala City, and Buenos Aires. That international setup supported clinical development, manufacturing, and commercial execution, but it also underscored the complexity of the organization. In competitive terms, Athenex operated in a crowded global oncology market where capital access, regulatory milestones, and trial outcomes are critical differentiators. Its positioning depended less on scale and more on whether its technology could generate clinically meaningful and approvable products. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1300699/000119312519313488/d838422dex991.htm?utm_source=openai))
Recent SEC disclosures and filings show a company that had entered a difficult strategic and financial phase, with management focusing on preserving and advancing the remaining platform assets while operating under heightened uncertainty. For investors, especially French, Belgian, and Swiss readers screening Form 4 insider transactions, Athenex should be viewed as a high-risk biotech case study rather than a mature commercial pharmaceutical platform. The investment thesis historically hinged on pipeline execution, regulatory progress, and the ability to convert scientific promise into durable commercial value. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1300699/000095017023008734/atnx-20221231.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
